Literature DB >> 28846213

Proteome Dynamics in Biobanked Horse Peripheral Blood Derived Lymphocytes (PBL) with Induced Autoimmune Uveitis.

Stefanie M Hauck1, Marlen F Lepper1, Michael Hertl2, Walter Sekundo3, Cornelia A Deeg4,5.   

Abstract

Equine recurrent uveitis is the only spontaneous model for recurrent autoimmune uveitis in humans, where T cells target retinal proteins. Differences between normal and autoaggressive lymphocytes were identified in this study by analyzing peripheral blood derived lymphocytes (PBL) proteomes from the same case with interphotoreceptor retinoid binding protein induced uveitis sampled before (Day 0), during (Day 15), and after uveitic attack (Day 23). Relative protein abundances of PBL were investigated in a quantitative, label-free differential proteome analysis in cells that were kept frozen for 14 years since the initial experiment. Quantitative data could be acquired for 2632 proteins at all three time points. Profound changes (≥2-fold change) in PBL protein abundance were observed when comparing Day 0 with 15, representing acute inflammation (1070 regulated proteins) and Day 0 with 23 (cessation; 1571 regulated). Significant differences applied to proteins with functions in integrin signaling during active uveitis, involving "Erk and pi-3 kinase are necessary for collagen binding in corneal epithelia," "integrins in angiogenesis," and "integrin-linked kinase signaling" pathways. In contrast, at cessation of uveitic attack, significantly changed proteins belonged to pathways of "nongenotropic androgen signaling," "classical complement pathway," and "Amb2 integrin signaling." Several members of respective pathways were earlier shown to be changed in naturally occurring uveitis, underscoring the significance of these findings here and proofing the value of the induced model in mimicking spontaneous autoimmune uveitis. All MS data have been deposited to the ProteomeXchange consortium via the PRIDE partner repository (dataset identifier PXD005580).
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Erk; PBL; biobanked cells; ilk; immune proteome; inflammation; lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 28846213     DOI: 10.1002/pmic.201700013

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  6 in total

1.  Interaction of septin 7 and DOCK8 in equine lymphocytes reveals novel insights into signaling pathways associated with autoimmunity.

Authors:  Melanie Schauer; Kristina J H Kleinwort; Roxane L Degroote; Carmen Wiedemann; Elisabeth Kremmer; Stefanie M Hauck; Cornelia A Deeg
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

2.  Horses with equine recurrent uveitis have an activated CD4+ T-cell phenotype that can be modulated by mesenchymal stem cells in vitro.

Authors:  Laurel K Saldinger; Seldy G Nelson; Rebecca R Bellone; Mary Lassaline; Maura Mack; Naomi J Walker; Dori L Borjesson
Journal:  Vet Ophthalmol       Date:  2019-08-22       Impact factor: 1.644

3.  IL8 and PMA Trigger the Regulation of Different Biological Processes in Granulocyte Activation.

Authors:  Roxane L Degroote; Maria Weigand; Stefanie M Hauck; Cornelia A Deeg
Journal:  Front Immunol       Date:  2020-01-14       Impact factor: 7.561

Review 4.  Immunological Insights in Equine Recurrent Uveitis.

Authors:  Roxane L Degroote; Cornelia A Deeg
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

5.  Pre-Activated Granulocytes from an Autoimmune Uveitis Model Show Divergent Pathway Activation Profiles upon IL8 Stimulation In Vitro.

Authors:  Anne L C Hoffmann; Stefanie M Hauck; Cornelia A Deeg; Roxane L Degroote
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208

6.  Peripheral blood bovine lymphocytes and MAP show distinctly different proteome changes and immune pathways in host-pathogen interaction.

Authors:  Kristina J H Kleinwort; Stefanie M Hauck; Roxane L Degroote; Armin M Scholz; Christina Hölzel; Erwin P Maertlbauer; Cornelia Deeg
Journal:  PeerJ       Date:  2019-11-25       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.